These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 31512802

  • 1. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients.
    Newland DM, Royston MJ, McDonald DR, Nemeth TL, Wallace-Boughter K, Carlin K, Horslen S.
    Pediatr Transplant; 2019 Dec; 23(8):e13573. PubMed ID: 31512802
    [Abstract] [Full Text] [Related]

  • 2. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S, Pankewycz O.
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [Abstract] [Full Text] [Related]

  • 3. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F, Zieroth S, Rao V, Ross H, Delgado DH.
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.
    Ali H, Soliman KM, Shaheen I, Kim JJ, Kossi ME, Sharma A, Pararajasingam R, Halawa A.
    Int Urol Nephrol; 2020 Apr; 52(4):791-802. PubMed ID: 32170593
    [Abstract] [Full Text] [Related]

  • 8. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.
    Am J Nephrol; 2015 Apr; 41(1):16-27. PubMed ID: 25612603
    [Abstract] [Full Text] [Related]

  • 9. Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants.
    Hafeez MS, Haq MU, Bakhthiyar SS, Azhar K, Awan AAY, Ramana Murthy BV, Abbas R.
    Transpl Immunol; 2022 Dec; 75():101733. PubMed ID: 36347493
    [Abstract] [Full Text] [Related]

  • 10. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
    Ganschow R, Grabhorn E, Schulz A, Von Hugo A, Rogiers X, Burdelski M.
    Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
    [Abstract] [Full Text] [Related]

  • 11. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
    Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J.
    Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
    [Abstract] [Full Text] [Related]

  • 12. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A.
    Transplantation; 2003 Mar 27; 75(6):796-9. PubMed ID: 12660504
    [Abstract] [Full Text] [Related]

  • 13. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.
    Cai J, Terasaki PI.
    Transplantation; 2010 Dec 27; 90(12):1511-5. PubMed ID: 21057388
    [Abstract] [Full Text] [Related]

  • 14. Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies - a retrospective study.
    Goumard A, Sautenet B, Bailly E, Miquelestorena-Standley E, Proust B, Longuet H, Binet L, Baron C, Halimi JM, Büchler M, Gatault P.
    Transpl Int; 2019 Aug 27; 32(8):820-830. PubMed ID: 30903722
    [Abstract] [Full Text] [Related]

  • 15. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 27; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
    Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D, Guertin MC.
    J Heart Lung Transplant; 2007 Mar 27; 26(3):258-63. PubMed ID: 17346628
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S, Paritala P, Rao Ch UM, Athmakuri SM, Reddy VS, Sahariah S.
    Saudi J Kidney Dis Transpl; 2014 Jan 27; 25(1):9-15. PubMed ID: 24434376
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Basiliximab and Anti-Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis.
    Ansari D, Höglund P, Andersson B, Nilsson J.
    J Am Heart Assoc; 2015 Dec 31; 5(1):. PubMed ID: 26722127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.